Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: A randomized controlled study

Peritoneal Dialysis International

Volumn 28, Issue 1, 2008, Pages 44-52

  Pajek, Jernej ^a   Kveder, Radoslav ^a   Bren, Andrej ^a   Guček, Andrej ^a   Ihan, Alojz ^b   Osredkar, Joško ^a   Lindholm, Bengt ^c  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bicarbonate lactate solution; Flow cytometry; Glucose degradation products; Inflammation

Indexed keywords

BICARBONATE; BUFFER; C REACTIVE PROTEIN; CA 125 ANTIGEN; CD14 ANTIGEN; DIALYSIS FLUID; GLUCOSE DEGRADATION PRODUCT; HLA DR ANTIGEN; INTERLEUKIN 6; LACTIC ACID;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BIOCOMPATIBILITY; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; KIDNEY FAILURE; MALE; PERITONEUM CELL; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC DISEASE; TREATMENT DURATION; ASCITES FLUID; MACROPHAGE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PERITONITIS; TIME;

ADULT; AGED; ASCITIC FLUID; BICARBONATES; BUFFERS; C-REACTIVE PROTEIN; CA-125 ANTIGEN; CROSS-OVER STUDIES; DIALYSIS SOLUTIONS; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-6; LACTIC ACID; MACROPHAGES; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONITIS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 42449145655     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080802800109     Document Type: Article

References (47)

1. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003; 14:1871-9.
2. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17:1684-8.
3. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimburger O, Lindholm B. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 2004; 24: 327-39.
4. Libetta C, De Nicola L, Rampino T, De Simone W, Memoli B. Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int 1996; 49: 506-11.
5. Davies SJ, Suassuna J, Ogg CS, Cameron JS. Activation of immunocompetent cells in the peritoneum of patients treated with CAPD. Kidney Int 1989; 36:661-8.
6. Brauner A, Hylander B, Jacobson SH, Moshfegh A, Lundahl J. Increased expression of CD25 and HLA-DR on lymphocytes recruited into the peritoneal cavity in non-infected CAPD patients. Inflammation 2001; 25:399-404.
7. Brauner A, Lu Y, Hallden G, Hylander B, Lundahl J. Difference in the blood monocyte phenotype between uremic patients and healthy controls: its relation to monocyte differentiation into macrophages in the peritoneal cavity. Inflammation 1998; 22:55-66.
8. Viedma Contreras JA. Leucocyte activation markers in clinical practice. Clin Chem Lab Med 1999; 37:607-22.
9. Zareie M, Hekking LH, Welten AG, Driesprong BA, Schadee-Eestermans IL, Faict D, et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18:2629-37.
10. van Bronswijk H, Verbrugh HA, Bos HJ, Heezius EC, Oe PL, van der Meulen J, et al. Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro. Perit Dial Int 1989; 9:197-202.
11. Cendoroglo M, Sundaram S, Groves C, Ucci AA, Jaber BL, Pereira BJ. Necrosis and apoptosis of polymorphonuclear cells exposed to peritoneal dialysis fluids in vitro. Kidney Int 1997; 52:1626-34.
12. Witowski J, Bender TO, Wisniewska-Elnur J, Ksiazek K, Passlick-Deetjen J, Breborowicz A, et al. Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se. Perit Dial Int 2003; 23:381-90.
13. Okabe E, Tomo T, Tezono K, Kikuchi H, Kadota J, Nasu M. Synergistic cytotoxicity of acidity and glucose degradation products in peritoneal dialysis fluid. J Artif Organs 2004; 7:155-60.
14. Welten AG, Schalkwijk CG, ter Wee PM, Meijer S, van den Born J, Beelen RJ. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 2003; 23:213-21.
15. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84:489-97.
16. Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 2004; 6:1219-25.
17. Boulanger E, Wautier MP, Wautier JL, Boval B, Panis Y, Wernert N, et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002; 61: 148-56.
18. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105:816-22.
19. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17:199-207.
20. Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N; Bicarbonate/Lactate Study Group. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001; 21(Suppl 3):S102-7.
21. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
22. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution - clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20: 516-23.
23. Schalkwijk CG, ter Wee PM, Teerlink T. Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis (PD) fluids and PD fluids based on glucose polymers or amino acids. Perit Dial Int 2000; 20:784-801.
24. Senn S. Cross-over Trials in Clinical Research. Chichester, UK: John Wiley & Sons Ltd; 1993.
25. Pecoits-Filho R, Araujo MRT, Lindholm B, Stenvinkel P, Abensur H, Romao JE, et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17: 1480-6.
26. Sundaram S, Cendoroglo M, Cooker LA, Jaber BL, Faict D, Holmes CJ, et al. Effect of two-chambered bicarbonate lactate-buffered peritoneal dialysis fluids on peripheral blood mononuclear cell and polymorphonuclear cell function in vitro. Am J Kidney Dis 1997; 30:680-9.
27. MacKenzie RK, Holmes CJ, Moseley A, Jenkins JP, Williams JD, Coles GA, et al. Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion. J Am Soc Nephrol 1998; 9:1499-506.
28. Mackenzie RK, Jones S, Moseley A, Holmes CJ, Argyle R, Williams JD, et al. In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function. Am J Kidney Dis 2000; 35:112-21.
29. Jones S, Holmes CJ, Mackenzie RK, Stead R, Coles GA, Williams JD, et al. Continuous dialysis with bicarbonate/lactate-buffered peritoneal dialysis fluids results in a long-term improvement in ex vivo peritoneal macrophage function. J Am Soc Nephrol 2002; 13(Suppl 1):597-103.
30. Mortier S, De Vriese AS, McLoughlin RM, Topley N, Schaub TP, Passlick-Deetjen J, et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003; 14:1296-306.
31. Suassuna JH, Das Neves FC, Hartley RB, Ogg CS, Cameron JS. Immunohistochemical studies of the peritoneal membrane and infiltrating cells in normal subjects and in patients on CAPD. Kidney Int 1994; 46:443-54.
32. Jonasson P, Albrektsson A, Ljungman S, Wieslander A, Braide M. Peritoneal leukocyte survival and respiratory burst responses in patients treated with a low glucose degradation and high pH peritoneal dialysis fluid. Int J Artif Organs 2003; 26:121-8.
33. Catalan MP, Reyero A, Egido J, Ortiz A. Acceleration of neutrophil apoptosis by glucose-containing peritoneal dialysis solutions: role of caspases. J Am Soc Nephrol 2001; 12:2442-9.
34. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11:729-39.
35. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
36. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001; 21:560-7.
37. Visser CE, Brouwer-Steenbergen JJ, Betjes MG, Koomen GC, Beelen RH, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995; 10:64-9.
38. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51:888-93.
39. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al; Bicarbonate/Lactate Study Group. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59:1529-38.
40. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
41. Pecoits-Filho R, Lindholm B, Stenvinkel P. End-stage renal disease: a state of chronic inflammation and hyperleptinemia. Eur J Clin Invest 2003; 33:527-8.
42. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 1995; 154:882-92.
43. Suliman ME, Heimbürger O, Bárány P, Anderstam B, Pecoits-Filho R, Rodríguez Ayala E, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14:1614-22.
44. Schwedler S, Schinzel R, Vaith P, Wanner C. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int Suppl 2001; 78:S32-6.
45. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195-200.
46. Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, et al. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2001; 12:814-21.
47. Chung SH, Heimbürger O, Stenvinkel P, Qureshi AR, Lindholm B. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 2003; 18:590-7.